Adjuvant immunotherapy for melanoma.

Area of Science:

• Oncology
• Immunology
• Melanoma Research

Background:

• Melanoma treatment often involves adjuvant therapies post-surgery.
• Immunotherapy aims to stimulate the patient's immune system against cancer cells.

Purpose of the Study:

• To evaluate the efficacy of adjuvant immunotherapy in melanoma patients.
• To assess projected and observed survival rates following treatment.

Main Methods:

• Administered adjuvant active specific homologous cell protein preparation immunotherapy.
• Treated 84 lymph-node-negative and 25 lymph-node-positive melanoma patients.
• Followed patients for over 2 years post-surgery.

Main Results:

• Projected 5-year survival rates exceeded expected outcomes across stages.
• Stage I melanoma patients showed a 90% projected 5-year survival.
• Stage II melanoma patients had a 68% projected 5-year survival.

Conclusions:

• Adjuvant immunotherapy demonstrated improved survival in melanoma patients.
• The observed survival rates suggest a beneficial effect of the immunotherapy regimen.
• Further randomized studies are warranted to confirm these findings.